ICD-11 code 2A80, also known as Follicular lymphoma, is a type of non-Hodgkin’s lymphoma characterized by the abnormal growth of B-lymphocytes in the lymph nodes. This slow-growing cancer usually presents as painless swelling in the lymph nodes, often in the neck, armpits, or groin. It is typically diagnosed in adults and is considered a low-grade or indolent lymphoma.
Follicular lymphoma is one of the most common types of non-Hodgkin’s lymphoma, accounting for about 20-30% of all cases. It is classified as a B-cell lymphoma, meaning it originates in B-lymphocytes, a type of white blood cell that plays a key role in the immune system. While the exact cause of follicular lymphoma is unknown, certain risk factors, such as age, family history, and exposure to certain chemicals, may increase the likelihood of developing this disease.
The prognosis for follicular lymphoma varies depending on the stage of the disease at diagnosis and other factors, such as the patient’s age and overall health. Treatment options for follicular lymphoma may include watchful waiting, chemotherapy, immunotherapy, radiation therapy, or targeted therapy. In some cases, a stem cell transplant may be recommended for patients with recurrent or refractory disease. Overall, the goal of treatment is to control the cancer, relieve symptoms, and improve the patient’s quality of life.
Table of Contents:
- #️⃣ Coding Considerations
- 🔎 Symptoms
- 🩺 Diagnosis
- 💊 Treatment & Recovery
- 🌎 Prevalence & Risk
- 😷 Prevention
- 🦠 Similar Diseases
#️⃣ Coding Considerations
The SNOMED CT code equivalent to the ICD-11 code 2A80 for Follicular lymphoma is 86407004. This specific code in the Systematized Nomenclature of Medicine Clinical Terms (SNOMED CT) database is crucial for accurately identifying and coding cases of Follicular lymphoma in medical records. This harmonization between different coding systems ensures consistency and interoperability in healthcare data exchange.
Having a standardized code such as 86407004 for Follicular lymphoma allows for improved communication among healthcare providers, researchers, and policymakers. It enables efficient data analysis, research, and quality improvement efforts related to this particular type of cancer. By utilizing SNOMED CT in conjunction with ICD-11 codes, healthcare professionals can ensure that patients receive appropriate care and treatment tailored to their specific diagnosis of Follicular lymphoma.
In the United States, ICD-11 is not yet in use. The U.S. is currently using ICD-10-CM (Clinical Modification), which has been adapted from the WHO’s ICD-10 to better suit the American healthcare system’s requirements for billing and clinical purposes. The Centers for Medicare and Medicaid Services (CMS) have not yet set a specific date for the transition to ICD-11.
The situation in Europe varies by country. Some European nations are considering the adoption of ICD-11 or are in various stages of planning and pilot studies. However, as with the U.S., full implementation may take several years due to similar requirements for system updates and training.
🔎 Symptoms
The symptoms of 2A80 (Follicular lymphoma) can vary among individuals, but commonly include painless swollen lymph nodes in the neck, armpits, or groin. This swelling may be noticed during physical examinations or self-examining the body. Fatigue, fever, night sweats, and unexplained weight loss are also common symptoms of follicular lymphoma. These systemic symptoms may indicate that the cancer has spread beyond the lymph nodes and affected other organs in the body.
Some individuals with follicular lymphoma may experience symptoms related to anemia, such as weakness, dizziness, and shortness of breath. This is due to the disease’s impact on the bone marrow’s ability to produce red blood cells. In more advanced cases, patients may develop symptoms related to the compression of nearby structures by enlarged lymph nodes. These symptoms can include chest pain, difficulty breathing, abdominal pain, or neurologic symptoms if the lymph nodes compress nerves.
It is important to note that some individuals with follicular lymphoma may not experience any symptoms initially, as the disease can progress slowly over time. However, as the cancer advances, symptoms may become more pronounced and impact the individual’s quality of life. It is crucial for individuals experiencing any persistent symptoms or changes in their health to seek medical evaluation and appropriate testing to identify the underlying cause, including the possibility of follicular lymphoma.
🩺 Diagnosis
Diagnosis of 2A80 (Follicular lymphoma) typically begins with a comprehensive medical history and physical examination. The presence of common symptoms such as painless swelling in the lymph nodes, fever, and weight loss may prompt further investigation. Blood tests, including a complete blood count and blood chemistry panel, can provide valuable information about the patient’s overall health and potential abnormalities that may suggest the presence of lymphoma.
Imaging studies such as computed tomography (CT) scans, magnetic resonance imaging (MRI), and positron emission tomography (PET) scans are commonly used to visualize the lymph nodes and other organs to determine the extent of the disease. These scans can help identify the location and size of any tumors and assess their response to treatment. A bone marrow biopsy is often performed to confirm the presence of lymphoma cells in the bone marrow, which may indicate advanced disease.
A lymph node biopsy is considered the gold standard for confirming a diagnosis of follicular lymphoma. During this procedure, a small sample of lymph node tissue is removed and examined under a microscope for the presence of cancer cells. The biopsy can also help determine the grade of the lymphoma, which is important for guiding treatment decisions. In some cases, a specialized test called flow cytometry may be performed on the biopsy sample to characterize the lymphoma cells and assess their response to certain treatments.
💊 Treatment & Recovery
Treatment and recovery methods for 2A80 (Follicular lymphoma) often depend on the stage of the disease and the overall health of the patient. Common treatment options include watchful waiting, chemotherapy, immunotherapy, radiation therapy, and stem cell transplant. Watchful waiting may be recommended for patients with slow-growing follicular lymphoma who do not have symptoms.
Chemotherapy, which involves the use of drugs to kill cancer cells, is a standard treatment for follicular lymphoma. This treatment may be used alone or in combination with other therapies. Immunotherapy is another option for treating follicular lymphoma, as it helps the immune system to recognize and attack cancer cells. Radiation therapy may be used to target specific areas of the body affected by the disease.
For some patients with follicular lymphoma, a stem cell transplant may be recommended. This procedure involves replacing damaged bone marrow with healthy stem cells to help the body produce new blood cells. Recovery from treatment for 2A80 (Follicular lymphoma) can vary depending on the individual patient and the specific treatment plan. It is important for patients to follow their healthcare provider’s recommendations for monitoring and follow-up care to ensure the best possible outcome.
🌎 Prevalence & Risk
In the United States, Follicular lymphoma is the most common indolent non-Hodgkin lymphoma, comprising approximately 20% of all cases. It has an annual incidence rate of about 3 per 100,000 individuals, with a slight predilection for older age groups. The overall prevalence of Follicular lymphoma in the United States is estimated to be around 18,000 cases.
In Europe, Follicular lymphoma accounts for approximately 40% of all indolent non-Hodgkin lymphoma cases, making it the most prevalent subtype in the region. The annual incidence rate varies by country, with an average of 2-3 cases per 100,000 individuals. The prevalence of Follicular lymphoma in Europe is estimated to be around 45,000 cases.
In Asia, Follicular lymphoma is less common compared to Western countries, comprising around 10% of all indolent non-Hodgkin lymphoma cases. The annual incidence rate is lower than in the United States and Europe, ranging from 1 to 2 cases per 100,000 individuals. The prevalence of Follicular lymphoma in Asia is estimated to be around 8,000 cases.
In Africa, Follicular lymphoma is relatively rare compared to other regions, comprising less than 5% of all indolent non-Hodgkin lymphoma cases. The annual incidence rate is lower than in Western countries, with an average of 1 case per 100,000 individuals. The prevalence of Follicular lymphoma in Africa is estimated to be around 2,000 cases.
😷 Prevention
One approach to preventing 2A80, also known as Follicular lymphoma, is through the identification of risk factors associated with the disease. Understanding the factors that may increase the likelihood of developing follicular lymphoma can inform individuals and healthcare professionals on measures to reduce these risks. Genetic predisposition, environmental exposures, and certain infections have been identified as potential risk factors for the development of follicular lymphoma.
Individuals with a family history of lymphoma or other blood cancers may be at higher risk for developing follicular lymphoma. Therefore, genetic counseling and testing can be recommended for those with a family history of the disease. Additionally, certain environmental exposures, such as pesticides and chemicals, have been associated with an increased risk of developing lymphoma. Avoiding or minimizing exposure to these chemicals may help reduce the risk of developing follicular lymphoma.
Furthermore, infections such as human T-cell leukemia virus type 1 (HTLV-1) and Epstein-Barr virus have been linked to an increased risk of developing follicular lymphoma. Practicing good hygiene, avoiding contact with infected individuals, and getting vaccinated against viruses associated with lymphoma may help prevent the development of the disease. Overall, maintaining a healthy lifestyle, including regular exercise, a balanced diet, and avoiding harmful environmental exposures, may contribute to lowering the risk of developing follicular lymphoma.
🦠 Similar Diseases
Diseases similar to Follicular lymphoma (2A80) include Small lymphocytic lymphoma (Z85B) and Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (2A1A). Small lymphocytic lymphoma is a form of chronic lymphocytic leukemia involving lymphocytes that resemble small lymphocytes in peripheral blood. Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue typically arises in extranodal sites such as the stomach, salivary glands, thyroid, lung, or skin.
Another related disease is Mantle cell lymphoma (2A90), a rare and aggressive form of non-Hodgkin lymphoma that arises from the outer edge (mantle zone) of a lymph node. Mantle cell lymphoma is often diagnosed at an advanced stage and typically requires aggressive treatment. Additionally, Diffuse large B-cell lymphoma (2B90) is another type of non-Hodgkin lymphoma that is more aggressive than Follicular lymphoma. This disease is characterized by large B-cells that grow more rapidly.
Hairy cell leukemia (Z85C) is yet another disease similar to Follicular lymphoma. Hairy cell leukemia is a rare type of chronic leukemia that primarily affects B-lymphocytes. It is characterized by abnormal B-cells with hair-like projections on their surface. This disease tends to progress slowly and may be treated with targeted therapies. Lastly, Burkitt lymphoma (2B85) is a fast-growing type of non-Hodgkin lymphoma that can affect the jaw, central nervous system, bowel, kidneys, or other organs. Burkitt lymphoma requires intensive treatment but often has a good prognosis with appropriate therapy.